

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jane Hirsh, Roman V. Rariy and Michael Heffernan

Serial No.: 10/690,872

Art Unit: 1618

Filed: October 22, 2003

Examiner: Leah H. Schlientz

For: *PULSATILE RELEASE COMPOSITIONS OF MILNACIPRAN*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including one (1) page of Form PTO-1449, copies of the seven (7) documents cited therein, a copy of the European Supplementary Search Report, mailed December 15, 2006, in the corresponding EP application 03809957.8, a copy of the European Supplementary Search Report, mailed December 4, 2006, in the related EP application 03809613.7, and a copy of a translation of cited Japanese Publication No. 2003-277252 obtained from the Japanese Patent Office website.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c) after a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1329.

Certification Under 37 C.F.R. §1.97 (e)(1)

Each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
0 759 299	02-26-1997	Eli Lilly Co.	EP
2003 277252	10-02-2003	Asahi Chemical Corp.	JP
WO 99/059593	11-25-1999	Eli Lilly Co.	PCT
WO 00/040224	07-13-2000	Elan Corp PLC	PCT
WO 04/037190	05-06-2004	Collegium Pharmaceutical, Inc.	PCT
WO 04/039361	05-13-2004	Collegium Pharmaceutical, Inc.	PCT
WO 04/067039	08-12-2004	Collegium Pharmaceutical, Inc.	PCT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

/Patrea L. Pabst/

Patrea L. Pabst

Reg. No. 31,284

Dated: March 1, 2007

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2151 (Telephone)
(404) 879-2160 (Fax)